1. Dustin ML, Springer TA (1988) Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107:321–331
2. EMEA (2000) EMEA public statement on infliximab (Remicade)—reports of tuberculosis infections. Accessed 17 January 2006 http://www.emea.eu.int/pdfs/human/press/pus/444500en.pdf
3. FDA (1995) COSTART: coding symbols for thesaurus of adverse reaction terms, 5th edn. pp 1–540
4. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073–3080
5. Gottlieb AB, Gordon KB, Hamilton TK, Caro I, Kwon P, Compton P (2005) Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Poster presented at the 63rd Annual Meeting of the American Academy of Dematology (AAD)